Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Neuroinflammation has long been considered a potential contributor to neurodegenerative disorders that result in dementia. Accumulation of abnormal protein aggregates in Alzheimer’s disease, frontotemporal dementia, and dementia with Lewy bodies is associated with the activation of microglia and astrocytes into proinflammatory states, and chronic low-level activation of glial cells likely contributes to the pathological changes observed in these and other neurodegenerative diseases. The 18 kDa translocator protein (TSPO) is a key biomarker for measuring inflammation in the brain via positron emission tomography (PET). Increased TSPO density has been observed in brain tissue from patients with neurodegenerative diseases and colocalizes to activated microglia and reactive astrocytes. Several radioligands have been developed to measure TSPO density in vivo with PET, and these have been used in clinical studies of different dementia syndromes. However, TSPO radioligands have limitations, including low specific-to-nonspecific signal and differential affinity to a polymorphism on the TSPO gene, which must be taken into consideration in designing and interpreting human PET studies. Nonetheless, most PET studies have shown that increased TSPO binding is associated with various dementias, suggesting that TSPO has potential as a biomarker to further explore the role of neuroinflammation in dementia pathogenesis and may prove useful in monitoring disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726 · cited 1×
“In such a scenario, the evidence suggests that the amount of microglial activation in the second peak would continue to rise as the dementia process worsens (Calsolaro & Edison, 2016).”
BackgroundPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
A polarizing question: do M1 and M2 microglia exist?
Ransohoff, R. M. (2016) · Nature Neuroscience · doi:10.1038/nn.4338 · Cited by 1,573
Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.
(1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.416 · Cited by 1,331
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 2×
“…a proposed pathogenic contributor to diffuse Lewy body disease (DLBD), which includes the aforementioned PDD and DLB. DLBD is defined by aggregated α-synuclein inclusions (i.e., Lewy bodies), which activate microglia in vitro and stimulate release of proinflammatory mediators (Zhang et al., 2005).”
BackgroundIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 3×
“Another small study found that four patients with progressive supranuclear palsy (PSP) displayed increased 11C-(R)-PK11195 binding in striatum, cerebellum, brainstem, thalamus, and the frontal lobe (Gerhard et al., 2006).”
BackgroundResultIn-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“For instance, studies found that 11C-(R)-PK-11195 binding was increased in AD patients and correlated with clinical severity (Cagnin et al., 2001; Edison et al., 2008; Yokokura et al., 2011).”
BackgroundOffice of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
Dickson, D. W., Bergeron, C., Chin, S. S., Duyckaerts, C., Horoupian, D., Ikeda, K., Jellinger, K., Lantos, P. L., Lippa, C. F., Mirra, S. S., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.935 · Cited by 724 · cited 1×
“However, another study found that the distribution of tau pathology commonly seen in CBD overlapped with the location of increased binding (Dickson et al., 2002).”
BackgroundPreclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564 · cited 2×
“In addition, MCI patients without evidence of amyloidopathy are less likely to have pathologically defined AD at autopsy (Vos et al., 2013), and they show less cognitive decline than amyloid-positive MCI patients (Landau, Horng, Fero, Jagust, & Alzheimer’s Adv Pharmacol.”
Background
Cited by
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Neuroimaging biomarkers for Alzheimer’s disease.
Márquez, F., & Yassa, M. A. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0325-5 · Cited by 289
Neuronal activity increases translocator protein (TSPO) levels
Notter, T., Schalbetter, S. M., Clifton, N. E., Mattei, D., Richetto, J., Thomas, K., Meyer, U., & Hall, J. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0745-1 · Cited by 118
Microglial Activation and Connectivity in Alzheimer Disease and Aging
Rauchmann, B., Brendel, M., Franzmeier, N., Trappmann, L., Zaganjori, M., Ersoezlue, E., Morenas‐Rodriguez, E., Guersel, S., Burow, L., Kurz, C., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26465 · Cited by 61
Metadata
- Authors
- Kreisl, W. C., Henter, I. D., & Innis, R. B.
- Venue
- Advances in Pharmacology
- Publisher
- Elsevier
- Published
- 2018
- Volume
- 82
- Pages
- 163-185
- ISSN
- 1054-3589 (ISSN-L)
- OpenAlex
- W2767448527
- Cited by
- 38
- References
- 42
- FWCI
- 17.23
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia. https://app.cochat.ai/papers/10.1016/bs.apha.2017.08.004
- The paper
- Kreisl, W. C., Henter, I. D., & Innis, R. B. (2018). Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia. Advances in Pharmacology. https://doi.org/10.1016/bs.apha.2017.08.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.